T10 - G2-T - 10 MG - Research Use Only

Product definition

What is Tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class, with Phase III data showing 22.5% mean body weight reduction at 72 weeks, the highest performance in obesity pharmacology trial history at publication.

Tirzepatide (Mounjaro, Zepbound; Eli Lilly) is a 39-amino-acid acylated peptide on a novel amino acid backbone — it does not share the GLP-1 or GIP sequences, but is engineered to achieve high affinity at both receptors. A C20 fatty diacid chain enables albumin binding and weekly dosing via a ~5-day half-life. FDA approved in 2022 for T2D (Mounjaro) and in 2023 for obesity (Zepbound). The mechanistic novelty is the GIP receptor contribution. Prior GLP-1RAs had established that GLP-1R activation alone produces significant weight reduction. The GIP receptor's role in adipose tissue metabolism — specifically, its expression on adipocytes and effects on lipid uptake, storage, and energy expenditure — had been debated before tirzepatide demonstrated that co-activating GIPR alongside GLP-1R produces incremental metabolic benefit beyond GLP-1R activation alone. The SURPASS and SURMOUNT phase 3 programs (>20,000 participants) constitute the most comprehensive dual incretin pharmacology dataset in the research literature.

Research context

What does the preclinical literature say about Tirzepatide?

Tirzepatide was developed by Eli Lilly following the clinical success of the GLP-1RA class, with the hypothesis that adding GIP receptor engagement to GLP-1R agonism would produce incremental metabolic benefit. The GIP receptor's role had been debated — some researchers hypothesized GIPR antagonism might improve outcomes, others hypothesized agonism would add benefit. Tirzepatide's Phase III results definitively resolved the question in favor of agonism for weight outcomes. The SURMOUNT-4 extension trial documented weight regain upon tirzepatide withdrawal, confirming the metabolic effects are pharmacologically maintained rather than permanent — an important finding for ongoing obesity biology research about the role of sustained incretin signaling. In preclinical models, tirzepatide's dual receptor pharmacology is studied to dissect the relative adipose tissue contributions of GIPR versus GLP-1R activation — using receptor-specific agonists and antagonists as research controls to attribute observed effects to the appropriate receptor pathway. This mechanistic dissection work constitutes an active area of metabolic research.